Neuralstem Inc: (AMEX: CUR)
$1.49
0.04 (2.76%)
Volume 2,132,474
May 17 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 1.40 - 1.59 |
| 52wk Low - High | 0.42 - 1.96 |
| Previous Close | 1.45 |
| Avg. Volume | 568,172 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 101.99 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.16 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.16 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
NA |
Zacks Industry Rank
|
91 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.16 |
| Current Quarter Estimate | -0.04 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-09-2013 |
| EPS Last Year | -0.15 |
| Expected Earnings Growth | NA |
Company Description
NEURALSTEM's patent-protected technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The Company expects that its first Investigational New Drug application will be for the treatment of Ischemic Paraplegia, a form of paraplegia that sometimes results from the surgery to repair aortic aneurysms and for which there is no effective treatment.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| NEURALSTEM INC | CUR | 1.49 | |
|
| AETERNA ZENTARS | AEZS | 2.10 | |
|
| ANIKA THERAPEUT | ANIK | 14.40 | |
|
| GENTIUM SPA-ADR | GENT | 8.87 | |
|
| AASTROM BIOSCI | ASTM | 0.57 | |
|
| ACHILLION PHARM | ACHN | 7.77 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.33 | |
|
| ALEXION PHARMA | ALXN | 102.90 | |
|
| ALKERMES INC | ALKS | 31.69 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
What's Happening In Regenerative Medicine
Jul 05, 2012
Neuralstem Pioneering Efforts In ALS
Jun 19, 2012
Report Not Available
Financials
| EPS TTM | -0.15 |
| Sales | 0 |
| Net Income | -11 |
| Price/Earnings | NA |
| Price/Book | 14.53 |
| Price/Cash Flow | NA |
| Price/Sales | 288.10 |
News
5 Stocks Under $10 Set to Soar - TheStreet.com
May 9, 2013
Neuralstem Wins FDA Approval to Begin Phase II Stem Cell Trial in Amytrophic Lateral Sclerosis - Benzinga
Apr 17, 2013
Neuralstem Inc. (CUR) CEO Richard Garr sells 12,000 Shares - GuruFocus
Feb 26, 2013
Neuralstem Issues License for Central Nervous System Therapy Surgical Devices to Cedars-Sinai - Benzinga
Feb 20, 2013
This Week in Biotech - TheMotleyFool
Jan 19, 2013
FDA OKs Neuralstem Trial Treating Spinal Cord Injuries With Stem Cells - TheMotleyFool
Jan 15, 2013
Dendreon Stock On Roll As Cell Therapy Hopes Revive - Investors Business Daily
Jan 14, 2013
UPDATE: Aegis Capital Reiterates Buy Rating, Raises PT on Neuralstem - Benzinga
Jan 14, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 1 |
| Average Target Price | 2.50 |
| Industry Rank by ABR | 91 out of 265 |
| Rank in Industry | 36 out of 155 |
